MCSTAP Case Discussion Series: Part 2: Buprenorphine in the Era of Fentanyl - June 20, 2024

This site is for learners who attended the live June 20, 2024, program to claim credit.

Claiming Credit 

Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the evaluation and claim your credit on the following page.

ADA statement: To request reasonable accommodations for a disability please contact MCSTAP@carelon.com, in writing, at least two weeks prior to the activity.

Target Audience

Primary care physicians, internists, family practice physicians, nurse practitioners, nurses, and physician assistants

Learning Objectives

Upon completion of this activity, participants will be able to:
  • Learn the nuts and bolts of buprenorphine prescribing
  • Become familiar with buprenorphine induction strategies and levels of evidence
  • Explore the impact of illicitly manufactured fentanyl on buprenorphine dosing and newer buprenorphine formulations
  • Review cases related to the impact of fentanyl on buprenorphine prescribing
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 1.00 MA Opioid Education Statement
  • 1.00 Participation
Course opens: 
06/20/2024
Course expires: 
08/19/2024
Rating: 
0
Zoom
United States
Christopher Shanahan, MD, MPH, FACP
MCSTAP Medical Director, CME Course Director
 
Jessica Gray, MD
Faculty
 
James Ledwith, Jr., MD
Faculty
 
 
BU CCE Operations Manager: Naomi Moeller

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program meets the criteria of the Massachusetts Board of Registration in Medicine for 1 hour of opioid education.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 1.00 MA Opioid Education Statement
  • 1.00 Participation
Please login or register to take this course.